COVID-19 EUAs: The Beginning of the End

1.5
RAC Credits
Virtual Programs Virtual Programs
Friday, 04 March 2022 (11:00 AM) - Friday, 04 March 2022 (12:30 PM) Eastern Time (US & Canada)

Recently, FDA released two draft guidance documents outlining the transition plan for devices granted an Emergency Use Authorization under the Covid-19 Pandemic to fully legally cleared products.  Many of the recommendations in these guidances leave industry professionals without a clear understanding of what FDA is trying to accomplish with the process. 

This live webcast will review FDA's proposed recommendations for devices with EUAs, recommended feedback manufacturers and regulatory professionals should provide to FDA prior to guidance finalization, and next steps to anticipate for products with an active EUA. 

Registration Fees & Deadlines

24 January 2022 - 4 March 2022: Member $0.00 | Nonmember $0.00

Learning Objectives 

By attending this program, you will:

  • Develop a working knowledge of the transition plan for EUA products to legally marketed devices.
  • Gain an understanding of the challenges and issues with the guidances as stated and how to provide direct feedback to FDA prior to the comment period closure.

Audience Learning Level

Beginning to intermediate

Content is introductory in nature and requires no requisite knowledge or experience to grasp concepts and related exercises. Basic educational activities are meant to establish a foundation of knowledge and/or competence that will be expanded upon in practice or in higher level activities.

Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.

Who Should Attend

Any company that currently holds an Emergency Use Authorization and intends to transition the products to legally marketed devices.

Instructors:

Michelle Lott

Michelle Lott, Principal & Founder

leanRAQA

Michelle Lott is founder and principal of leanRAQA. She has supported more than 100 companies with regulatory strategy, regulatory submissions, quality systems compliance, due diligence and technical support services. Lott’s clients delegate these things to her so they can focus on winning in the marketplace. She served a four-year term on the US Food and Drug Administration (FDA) Device Good Manufacturing Practices Advisory Committee (DGMP), and she has completed the RAPS Executive Development Program at the Kellogg School of Management at Northwestern University.


Event Policies

RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation. 

To transfer a registration, email support@raps.org with the event title, name of the original registrant and the contact information for the new attendee. 

 

Contact Us

For additional hands-on support, you can also connect with RAPS support 30 min prior to the workshophttps://www.raps.org/website/virtual-event-help

For account support, contact the RAPS Support Center: +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email support@raps.org.

Discover more of what matters to you

News »

  18;20;31;